01 April 2004
Interleukin 4 plasma levels in psoriasis vulgaris patients
Anna Zalewska, Janina Wyczółkowska, Bożena Dziankowska-Bartkowiak, Anna Sysa-JędrzejowskaMed Sci Monit 2004; 10(4): CR156-162 :: ID: 11637
Abstract
Background:Psoriasis is regarded as a Th1-cell type disease. Interleukin-4, a Th2 type cytokine, is diminished in psoriatic skin. It has been postulated that switching the cytokine profile from Th1 to Th2 may be of great help in the treatment of psoriasis. Some recent reports demonstrate a favorable role of IL-4 in the treatment of psoriasis. Therefore we decided to evaluate how IL-4 plasma levels fluctuate in the case of favorable treatment outcome observed in patients with clinically active and stable disease.Material/Methods: 17 patients with active psoriasis vulgaris, 17 with stable disease, and 22 age- and sex-matched healthy controls were included in the study. IL- 4 plasma levels were evaluated by the ELISA method twice – before treatment implementation and 4 weeks thereafter.Results: We observed statistically significant higher IL-4 plasma levels in the active psoriasis group both before treatment implementation (1[sup]st[/sup] examination) and after 4 weeks of treatment (2[sup]nd[/sup] examination) compared with both the control group (p<0.001) and the stable psoriasis group (1st examination: p<0.001, 2nd examination: p<0.01). There was no statistically significant difference in IL-4 plasma levels between the stable psoriasis and control groups in both examinations (p>0.05).
Conclusions: Our data seem to support the hypothesis of the existence of immunologically distinct psoriasis subtypes.
Keywords: Anthralin - therapeutic use, Ficusin - therapeutic use, Interleukin-4 - blood, Methotrexate - therapeutic use, Phototherapy, Psoriasis - blood, Psoriasis - therapy, Severity of Illness Index, Anthralin - therapeutic use, Ficusin - therapeutic use, Interleukin-4 - blood, Methotrexate - therapeutic use, Phototherapy, Psoriasis - therapy, Severity of Illness Index
849 19
Editorial
01 November 2023 : Editorial
Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is DeclaredDOI: 10.12659/MSM.942960
Med Sci Monit 2023; 29:e942960
In Press
28 Nov 2023 : Clinical Research
Impact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and ...Med Sci Monit In Press; DOI: 10.12659/MSM.942122
28 Nov 2023 : Clinical Research
Long-Term Outcomes of Decompression and Grafting in Acute Pathological Proximal Femur Fractures in Children...Med Sci Monit In Press; DOI: 10.12659/MSM.943031
27 Nov 2023 : Clinical Research
Comparison of Outcomes from Emergency Admissions to a Major Trauma Center in Turkey of 1646 Elderly Patient...Med Sci Monit In Press; DOI: 10.12659/MSM.942916
27 Nov 2023 : Clinical Research
Evaluating Modified Ultrasound-Guided Serratus Anterior Plane Block for Enhanced Postoperative Recovery in ...Med Sci Monit In Press; DOI: 10.12659/MSM.942757
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292